ImmunoGen shares are trading higher after the company announced results from the pivotal SORAYA trial of mirvetuximab soravtansine in ovarian cancer met the primary endpoint with confirmed objective response rate of 32.4%.

by Yogesh Tanwar | Nov 30, 2021 | Extra Jobs | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.